Kitov Pharmaceuticals price target raised to $12.50 from $10 at H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Kitov Pharmaceuticals to $12.50 after the FDA approved Consensi “on schedule.” The analyst reiterates a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.